Evaluations for Y-mAbs therapies YMAB have been provided by 4 analysts in the last three months, showing a mix of bullish and bearish outlooks.
In the table below you’ll find a summary of their recent ratings, revealing changing sentiments over the past 30 days and comparing them to previous months.
| Bullish | A little bullish | Indifferent | A little bearish | Bearish | |
|---|---|---|---|---|---|
| Total ratings | 3 | 1 | 0 | 0 | 0 |
| Last 30 days | 1 | 0 | 0 | 0 | 0 |
| 1 million ago | 2 | 1 | 0 | 0 | 0 |
| 2 million ago | 0 | 0 | 0 | 0 | 0 |
| 3 million ago | 0 | 0 | 0 | 0 | 0 |
Analysts provide more in-depth information through their 12-month price target ratings, revealing an average target of $23.75, a high estimate of $26.00 and a low estimate of $21.00. With an increase of 35.71%, the current average surpasses the previous average price target of $17.50.
Investigating analyst ratings: An elaborate study
A clear picture of the perception of Y-mAbs Therapeutics among financial experts is painted with an in-depth analysis of recent analyst actions. The summary below outlines key analysts, their recent ratings, and adjustments to ratings and price targets.
| Analyst | Analytics company | Action taken | Assessment | Current price target | Previous price target |
|---|---|---|---|---|---|
| Robert Burns | H. C. Wainwright & Co. | Raise | Acquire | $22.00 | $21.00 |
| Bill Maughan | Canaccor authenticity | Raise | Acquire | $26.00 | $22.00 |
| Etzer Darout | BMO Capital | Raise | Far surpass | $26.00 | $16.00 |
| Robert Burns | H. C. Wainwright & Co. | Raise | Acquire | $21.00 | $11.00 |
Key Insights:
- Action taken: Responding to changing market dynamics and business performance, analysts update their recommendations. Whether they “maintain”, “raise” or “lower” their position, this signifies their response to recent developments related to Y-mAbs therapy. This offers insight into analysts’ perspectives on the current state of the company.
- Assessment: Analysts reveal qualitative ratings for the shares, ranging from “Outperform” to “Underperform”. These ratings offer insight into expectations for Y-mAbs Therapeutics’ relative performance compared to the broader market.
- Price targets: Analysts set price targets as an estimate of a stock’s future value. Comparing current and previous price targets provides insight into how analyst expectations have changed over time. This information can be valuable to investors seeking to understand consensus views on the stock’s potential future performance.
Understanding these analyst ratings along with key financial indicators can offer valuable insights into Y-mAbs Therapeutics’ market position. Stay informed and make well-informed decisions with our ratings table.
Stay updated on Y-mAbs Therapeutics analysts’ ratings.
If you’re interested in following the news and performance of small-cap stocks, you can start by tracking them here.
Information on Y-mAbs therapy
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is primarily engaged in the development and commercialization of novel antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the Company’s first FDA-approved product and is a recombinant humanized immunoglobulin G, subtype 1k or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.
Y-mAbs Therapy: Insight into Financial Data
Market capitalization: Positioned above the industry average, the company’s market capitalization underlines its size superiority, indicative of a strong market presence.
Negative revenue trend: Examining Y-mAbs Therapeutics’ 3-month financials reveals some challenges. As of December 31, 2023, the company recorded a decline of approximately -25.71% in revenue growth, reflecting a decline in top-line earnings. Compared to its peers, revenue growth lags that of industry peers. The company achieved a below-average growth rate among its healthcare peers.
Net margin: The company’s net margin is exceptional and exceeds industry averages. With an impressive net margin of -4.23%, the company has strong profitability and effective cost control.
Return on equity (ROE): Y-mAbs Therapeutics’ financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a notable ROE of -0.98%, the company demonstrates efficient use of equity capital and strong financial health.
Return on Assets (ROA): Y-mAbs Therapeutics’ financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a notable ROA of -0.77%, the company demonstrates efficient use of resources and solid financial health.
Debt Management: Y-mAbs Therapeutics’ debt-to-equity ratio is lower than the industry average. With a ratio of 0.01the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
What are analyst ratings?
Analysts work in banking and financial systems and typically specialize in reporting on defined stocks or sectors. Analysts can participate in company conference calls and meetings, research company financial statements, and communicate with insiders to post “analyst ratings” for stocks. Analysts typically rate each stock once a quarter.
In addition to their standard ratings, some analysts contribute forecasts on metrics such as growth, earnings and revenue estimates, providing investors with additional guidance. Users of analyst ratings should be aware that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.